Literature DB >> 20036139

Fullerene-C60/liposome complex: Defensive effects against UVA-induced damages in skin structure, nucleus and collagen type I/IV fibrils, and the permeability into human skin tissue.

Shinya Kato1, Hisae Aoshima, Yasukazu Saitoh, Nobuhiko Miwa.   

Abstract

We previously reported biological safety of fullerene-C60 (C60) incorporated in liposome consisting of hydrogenated lecithin and glycine soja sterol, as Liposome-Fullerene (0.5% aqueous phase; a particle size, 76nm; Lpsm-Flln), and its cytoprotective activity against UVA. In the present study, Lpsm-Flln was administered on the surface of three-dimensional human skin tissue model, rinsed out before each UVA-irradiation at 4 J/cm(2), and thereafter added again, followed by 19-cycle-repetition for 4 days (sum: 76 J/cm(2)). UVA-caused corneum scaling and disruption of epidermis layer were detected by scanning electron microscopy. Breakdown of collagen type I/IV, DNA strand cleavage and pycnosis/karyorrhexis were observed in vertical cross-sections of UVA-irradiated skin models visualized with fluorescent immunostain or Hoechst 33342 stain. These skin damages were scarcely repressed by liposome alone, but appreciably repressed by Lpsm-Flln of 250 ppm, containing 0.75 ppm of C60-equivalent to a 1/3300-weight amount vs. the whole liposome. Upon administration with Lpsm-Flln [16.7 microM (12 ppm): C60-equivalent] on human abdomen skin biopsies mounted in Franz diffusion cells, C60 permeated after 24h into the epidermis at 1.86 nmol/g tissue (1.34 ppm), corresponding to 0.3% of the applied amount and a 9.0-fold dilution rate, but C60 was not detected in the dermis by HPLC, suggesting no necessity for considering a toxicity of C60 due to systemic circulation via dermal veins. Thus Lpsm-Flln has a potential to be safely utilized as a cosmetic anti-oxidative ingredient for UVA-protection. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036139     DOI: 10.1016/j.jphotobiol.2009.11.010

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  8 in total

1.  Photodynamic therapy with fullerenes in vivo: reality or a dream?

Authors:  Sulbha K Sharma; Long Y Chiang; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

2.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

3.  Chronic inflammatory cells and damaged limbal cells in pterygium.

Authors:  P Anguria; T Carmichael; S Ntuli; J Kitinya
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 4.  Functionalized fullerenes in photodynamic therapy.

Authors:  Ying-Ying Huang; Sulbha K Sharma; Rui Yin; Tanupriya Agrawal; Long Y Chiang; Michael R Hamblin
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

5.  Fullerenes as photosensitizers in photodynamic therapy: pros and cons.

Authors:  Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2018-07-25       Impact factor: 3.982

6.  Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma.

Authors:  Pawel Mroz; Yumin Xia; Daisuke Asanuma; Aaron Konopko; Timur Zhiyentayev; Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Usman J Khan; Tim Wharton; Michael R Hamblin
Journal:  Nanomedicine       Date:  2011-05-19       Impact factor: 5.307

7.  Growth and potential damage of human bone-derived cells on fresh and aged fullerene c60 films.

Authors:  Ivana Kopova; Lucie Bacakova; Vasily Lavrentiev; Jiri Vacik
Journal:  Int J Mol Sci       Date:  2013-04-26       Impact factor: 5.923

8.  Liposome formulation of fullerene-based molecular diagnostic and therapeutic agents.

Authors:  Zhiguo Zhou
Journal:  Pharmaceutics       Date:  2013-10-18       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.